PalindromX, the developer of a patented technology that facilitates more accurate diagnosis by improving the performance of conventional blood tests, has secured a six-figure investment to continue its proof of concept work.

PalindromX, the developer of a patented technology that facilitates more accurate diagnosis by improving the performance of conventional blood tests, has secured a six-figure investment to continue its proof of concept work.

The company raised £100,000 from Merseyside Special Investment Fund’s (MSIF) Liverpool Ventures Seed Fund. The proceeds will be used to take the company’s analytical methodology to the next phase of development where its viability and potential market demand are assessed.

MSIF was advised on the terms of its investment by Weightmans, led by partner and head of corporate John Schorah, assistant solicitor Lynne Rathbone and associate Sean Crotty.

Schorah said Weightmans has worked with MSIF on several of its investments. “On this occasion, it provided funding to PalindromX so as to assist with its valuable research and development of improved sensitivity for immunoassay techniques.”